Table 5.
PD-L1 expression stratified by clinicopathologic features
| Characteristic | PD-L1 TPS | Total (n) | Z | P value | ||
|---|---|---|---|---|---|---|
| < 1% n (%) | 1–49% n (%) | ≥50% n (%) | ||||
| Total | 32 (25.8) | 45 (36.3) | 47 (37.9) | 124 | ||
| Age, y | 124 | −1.038 | 0.299 | |||
| ≤ 55 | 13 (29.5) | 17 (38.6) | 14 (31.8) | |||
| > 55 | 19 (23.8) | 28 (35) | 33 (41.3) | |||
| Sex | 124 | −1.099 | 0.272 | |||
| Male | 23 (28.8) | 29 (36.3) | 28 (35.0) | |||
| Female | 9 (20.5) | 16 (36.4) | 19 (43.2) | |||
| Diagnosis | 119 | −2.47 | 0.013a | |||
| Adenocarcinoma | 23 (21.3) | 42 (38.9) | 43 (39.8) | 108 | ||
| Smoking status | 99 | −1.944 | 0.052 | |||
| Current or former | 13 (32.5) | 15 (37.5) | 12 (30.0) | |||
| Never | 9 (15.3) | 24 (40.7) | 26 (44.1) | |||
| Squamous cell carcinoma | 7 (63.6) | 2 (18.2) | 2 (18.2) | 11 | ||
| Smoking status | 8 | −0.77 | 0.643 | |||
| Current or former | 4 (66.7) | 2 (33.3) | 0 (0.0) | |||
| Never | 1 (50.0) | 0 (0.0) | 1 (50.0) | |||
| Smoking status | 111 | −2.63 | 0.009a | |||
| Current or former | 19 (38.0) | 18 (36.0) | 13 (26.0) | |||
| Never | 10 (16.4) | 24 (39.3) | 27 (44.3) | |||
Abbreviation: PD-L1 programmed cell death ligand-1, TPS tumor proportion score; astatistically significant